Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $2.97B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.93M
Average 1.71M
DYN Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Dyne Therapeutics, Inc.NASDAQ: DYN
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $14.98M rose 42.3% year over year, ahead of the -8.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 14.5% from the prior quarter. Over 3 fiscal years it compounded at +44.6% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +42.3% holds above the trailing-twelve-month pace of -8.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 45.85M USD
- Year-over-year change
- -0.0%
- 4-year CAGR
- +27.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.85M | -0.0% |
| FY2024 | 2024-12-31 | 45.86M | +129.6% |
| FY2023 | 2023-12-31 | 19.97M | +31.6% |
| FY2022 | 2022-12-31 | 15.18M | -13.5% |
| FY2021 | 2021-12-31 | 17.54M | — |
Stock-Based Compensation vs competitors
How DYN compares with its peers on the latest reported figures
- DYN's LTM Jun 2026 stock-based compensation of $39.28M is the 5th largest of the 11 companies compared; the peer median is $23.97M.
- Its year-over-year change of -8.1% is the 7th highest of 11, against a peer median of +2.2%.
- Over three fiscal years its annual growth of +44.6% compares with a peer median of +12.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.98B | +32410.1% | +56.9% | — | |
| LTM Sep 2026 | $132.29M | +4.4% | +10.1% | 13.8% | |
| LTM Mar 2026 | $111.37M | -39.8% | -19.1% | 5.1% | |
| LTM Jun 2026 | $84.66M | +15.0% | -12.3% | 8.4% | |
| LTM Jun 2026 | $39.28M | -8.1% | +44.6% | — | |
| LTM Mar 2026 | $26.2M | -9.4% | +12.2% | 81.7% | |
| LTM Mar 2026 | $21.73M | +42.8% | — | 30.3% | |
| LTM Mar 2026 | $19.27M | -0.0% | +25.6% | 335.8% | |
| LTM Mar 2026 | $18.73M | +52.9% | +30.9% | — | |
| LTM Mar 2026 | $10.03M | -22.0% | +30.6% | — | |
| LTM Mar 2026 | $7.15M | -15.9% | +1.9% | — | |
| Peer median (excluding DYN) | $23.97M | +2.2% | +12.2% | 22.0% | |
Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Depreciation & Amortization | 1.09M | 1.68M | 1.67M | 1.67M | 2.05M |
| Deferred Income Tax | 2.59M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 17.54M | 15.18M | 19.97M | 45.86M | 45.85M |
| Change in Working Capital | 9.26M | (5.38M) | 26.31M | (19.49M) | (3.4M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 13.7M | (1.24M) | 22.97M | (8.96M) | 8.25M |
| Other Working Capital | (4.45M) | (4.14M) | 3.34M | (10.54M) | (11.65M) |
| Other Non-Cash Items | (746K) | 2.97M | (173K) | (3M) | (1.49M) |
| Operating Cash Flow | (119.56M) | (153.65M) | (188.16M) | (292.37M) | (403.21M) |
| Capital Expenditures | (3.62M) | (3.07M) | (729K) | (2.38M) | (1.92M) |
| Acquisitions (Net) | 8K | 34K | 0 | 0 | 0 |
| Purchases of Investments | (236.72M) | (121.18M) | (44.26M) | (317.44M) | (180.53M) |
| Sales of Investments | 102.45M | 211.45M | 128.3M | 115.71M | 172.46M |
| Other Investing Activities | (8K) | (34K) | 0 | 35K | (18.76M) |
| Investing Cash Flow | (137.89M) | 87.2M | 83.31M | (204.08M) | (28.75M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 147.7M |
| Common Stock Issued | 157.24M | 36.86M | 52.37M | 773.05M | 742.61M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 584K | 529K | 1.95M | 36.84M | 0 |
| Financing Cash Flow | 157.82M | 37.39M | 54.32M | 809.9M | 890.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (99.63M) | (29.05M) | (50.53M) | 313.45M | 458.35M |
| Free Cash Flow | (123.18M) | (156.71M) | (188.89M) | (294.75M) | (405.13M) |
Dyne Therapeutics, Inc.
NASDAQ:DYN
Intrinsic Alpha fair value
Locked
Current Price
$15.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.